The purpose of the study was to assess the mechanism responsible for increased stroke risk in patients with atrial septal aneurysm (SA) and patent foramen ovale (PFO), and to determine the efficacy of medical therapy for preventing stroke recurrence or death. BACKGROUND Atrial septal aneurysm and PFO are associated with stroke. However, the mechanism for this association is undefined, and the efficacy of medical therapy has not been investigated in a randomized fashion.
OBJECTIVES
The purpose of the study was to assess the mechanism responsible for increased stroke risk in patients with atrial septal aneurysm (SA) and patent foramen ovale (PFO), and to determine the efficacy of medical therapy for preventing stroke recurrence or death. BACKGROUND Atrial septal aneurysm and PFO are associated with stroke. However, the mechanism for this association is undefined, and the efficacy of medical therapy has not been investigated in a randomized fashion.
METHODS
The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evaluated transesophageal echocardiography findings in patients enrolled in the Warfarin-Aspirin Recurrent Stroke Study, a randomized double-blind trial to evaluate the efficacy of warfarin compared with aspirin.
RESULTS
Large PFO and prominent eustachian valve (EV) or right atrial (RA) filamentous strands were found more frequently in patients with SA compared with those without SA (37.7% vs. 10.9%, p Ͻ 0.001 and 59.4% vs. 43.1%, p ϭ 0.02). Patients with SA and PFO had no significant difference in time to recurrent stroke or death compared with those having neither (hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.49 to 2.38, p ϭ 0.84; two-year event rates 15.9% vs. 14.5%). Patients with SA, PFO, and RA anatomy predisposing to paradoxical embolization also had no difference compared with those without these findings (HR 1.22, 95% CI 0.43 to 3.47, p ϭ 0.71; two-year event rates 18.2% vs. 14.2%). There was no significant difference in time to recurrent stroke or death between the patients treated with warfarin or aspirin (HR 1.00, 95% CI 0.22 to 4.47, p ϭ 1.0; two-year event rates 16.0% vs. 15.8%). CONCLUSIONS Atrial septal aneurysm is associated with the presence of large PFO and prominent EV or RA filamentous strands. On medical therapy, patients with SA and PFO did not experience increased risk of adverse events, and there was no difference between treatment results for warfarin and for aspirin. Atrial septal aneurysm (SA) and patent foramen ovale (PFO) have been associated, separately, with stroke, and a combination of SA and PFO has been shown to confer an especially high risk (1) (2) (3) (4) (5) (6) . However, the mechanism for this finding has not been clarified. Previously, it has been shown that large PFOs are more often found in cryptogenic stroke
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patients (7, 8) . Therefore, we sought to investigate the characteristics of PFO found in stroke patients with SA. The eustachian valve (EV) is a membrane-like structure in the right atrium, a remnant of right valve of sinus venosus that directs blood flow from the inferior vena cava (IVC) to the fossa ovalis area in the fetal period (9) . Prominence of EV in adult life is reported to cause a significant right-toleft shunt in the presence of interatrial communication by altering the blood flow pattern (10, 11) . Filamentous strands in right atrium which can span EV with atrial wall are also a remnant of right valve of sinus venosus (12, 13) . When an extensive network of strands is present, it is known as Chiari network, which has been associated with paradoxical embolization presumably by directing IVC flow towards the fossa ovalis area (14, 15) . Given these findings, we hypothesized that SA is associated with large PFO and that prominent EV or right atrial (RA) filamentous strands are more frequently found in patients with SA. The combination of a large PFO and a structure in right atrium diverting IVC flow toward the PFO would likely lead to an increased chance of paradoxical embolization. A recent report indicates a significantly increased recurrent stroke risk in patients with SA and PFO, compared with those having neither (16) . We have recently reported that on medical therapy the presence of SA in the overall group of stroke patients with PFO did not increase the adverse event rate beyond that seen with PFO alone (17) . However, this group was not compared with the patients with neither SA nor PFO, and cryptogenic stroke patients were not analyzed separately. Furthermore, the effect of RA anatomical variation on the adverse event rates in patients with SA and PFO was not investigated. There is an increasing use of percutaneous or surgical PFO closure to potentially prevent paradoxical embolic events (18 -21) . In order to define their proper role, it is necessary to rigorously assess the risk of adverse events in conventionally medically treated patients with PFO, particularly in a perceived high-risk group, such as those with SA, PFO, and RA anatomy predisposing to paradoxical embolization. Therefore, in the current study, we investigated whether the presence of SA and PFO, with or without RA anatomical variation, alters the event rates when compared with the patients without these findings.
METHODS
Patient recruitment. The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) was a 42-center study that tested the efficacy of medical therapy for stroke risk factors identified by transesophageal echocardiography (TEE) (17) . Patients were drawn from the Warfarin-Aspirin Recurrent Stroke Study (WARSS), a double-blind study to assess the efficacy of warfarin compared with aspirin for prevention of recurrent stroke or death in ischemic stroke patients (22) . Patient recruitment started in June 1993 and ended in June 1998. The PICSS patients consisted of WARSS patients undergoing TEE for any clinical purpose, as well as WARSS patients with cryptogenic stroke subtype who were solicited to undergo TEE for PICSS entry (17) . Clinical data were collected by the Data Management Center in the Stroke Unit of the Columbia-Presbyterian Medical Center. All protocols for WARSS and PICSS were approved by the institutional review board at each participating center, and informed consent was obtained from each participant. Eligibility. Patients age 30 to 85 years were eligible. Eligible patients experienced ischemic stroke within the previous 30 days and rated Ն3 on the Glasgow Outcome Scale (representing severe disability, moderate disability, no or minimal disability) (23) . Ineligible patients had baseline international normalized ratio (INR) above the normal range (Ͼ1.4), stroke related to a procedure, stroke attributable to a cardioembolic source, or planned to undergo surgery for high-grade carotid stenosis. Patients with a contraindication to TEE were not considered for PICSS entry. Stroke subtyping. All baseline strokes were subtyped by a local neurology principal investigator based on a predefined criteria modeled after the National Institute of Neurological Disorders and Stroke-Stroke Data Bank and Trial of Organon in Acute Stroke Therapy (24) . These subtypes were: lacunar, large vessel, cryptogenic, other determined cause, and conflicting mechanisms. Cryptogenic stroke typically has no definite source despite a thorough diagnostic evaluation (25) . Medications and blinding. Medications used were aspirin 325 mg tablets taken once daily, and warfarin in 2 mg scored tablets taken once daily, adjusted to achieve and maintain INR 1.4 to 2.8. Patients were randomized to active aspirin or warfarin and an identical placebo. No patients received two placebo or two active treatments. TEE protocol and analysis. All patients underwent TEE guided by a predefined protocol using either a biplane or multiplane TEE probe and the videotapes were sent to Columbia for central analysis. The TEE protocol emphasized extensive characterization of interatrial septum and RA anatomy. Saline contrast injection with and without Valsalva maneuver or cough was performed for PFO detection. Ongoing quality control was monitored with feedback to the site regarding TEE study quality.
All TEE tapes were analyzed by a single observer (S. H.). All measurements were made blinded to treatment assignment, stroke subtype, or outcome. The PFO was determined to be present if, upon saline contrast injection, there was appearance of at least one microbubble in the left atrium within three cardiac cycles following opacification of the right atrium (26, 27) . The PFO was distinguished from atrial septal defect by the presence of overlap of septum primum and secundum. The number of microbubbles was counted from an image demonstrating the maximum number on a video frame within three cardiac cycles from the opacification of right atrium (7, 28) . Measurements were made from resting contrast injection and in conjunction with Valsalva maneuver or cough, whichever demonstrated a larger PFO size or shunt. Each PFO was determined to be large or small, as previously described (17) .
The SA was defined as a motion of atrial septum into left or right atrium of at least 10 mm from its midline position (29) . Prominent EV was defined as a protrusion into the right atrium of 10 mm or more of linear membrane-like structure from the junction of right atrium with IVC in the image plane demonstrating the entrance of IVC into right atrium in a vertical plane using biplane probe, or an equivalent plane using multiplane probe. Right atrial filamentous strands were defined as freely mobile linear filamentous structures in RA with attachment to EV or to any aspect of RA wall. Inter-and intra-observer variability for determination of the presence of prominent EV or RA Kaplan-Meier curves were constructed and a Cox proportional hazards model was used to determine the relative hazard ratio and associated 95% confidence interval (CI) for subjects with SA and PFO compared with subjects with neither SA nor PFO. Similar analyses were performed comparing subjects with the combination of SA, PFO, and prominent EV or RA filamentous strands with subjects having none of these findings. These analyses were performed for the group as a whole, and in the cryptogenic stroke patients. In subjects with SA and PFO, warfarin was compared with aspirin. Reported event rates at two years were derived from the Kaplan-Meier curves, which adjusted for censoring. A value p Ͻ 0.05 was considered significant for all analyses.
RESULTS
The Table 1 , SA was strongly associated with the presence of PFO, and these PFOs were larger than those found without SA. Atrial septal aneurysm was associated with the presence of prominent EV or RA filamentous strands, and the combination of a large PFO and prominent EV or RA filamentous strands was strongly associated with the presence of SA. When a more stringent criteria of three or microbubbles for the presence of PFO, and 20 or more microbubbles for large PFO was applied, the findings did not change. Furthermore, when the patients were divided into those Ͻ50 years of age and those Ն50 years of age, in both groups, SA was associated with the presence of PFO and large PFO. End points. The analyses were adjusted for the 10 patients lost to follow-up using a prespecified imputation procedure (22) . Using this model, the overall primary event rate was 15.9%. Among the 600 patients with TEE images adequate for analysis of SA and PFO, there were a total of 92 end points (15.3%). Seventy-one strokes and 21 deaths occurred. Additionally, 34 TIAs occurred, including seven that occurred before the primary event. The rate of major hemorrhage was similar between the patients on warfarin and those on aspirin, but the rate of minor hemorrhage was significantly higher in patients on warfarin compared with those on aspirin (17) . Efficacy of medical therapy. In the overall patient population the event rate in patients with SA and PFO was compared with that in patients with neither SA nor PFO. Demographics, stroke characteristics, and risk factors were similar between these groups (Table 2) . Criteria for clinical variables have been previously defined (22) . In the overall group, there was no significant difference in time to recurrent stroke or death in those with SA and PFO compared with the patients with neither of these findings (Table 3) .
With the addition of TIA as an additional end point, there also was no significant difference. When the cryptogenic subtype was considered separately, there were no significant differences in the time to end point with and without inclusion of TIA (Table 3 ). We then compared the patients with SA and PFO, along with prominent EV or RA filamentous strands with those without any of these findings. Demographic and stroke characteristics and risk factors were similar between the comparison groups (Table 4 ). In the overall as well as in the cryptogenic subset, there was no difference in the time to end points between the groups with and without TIA as an additional end point (Table 5) . When the efficacy of warfarin and aspirin was compared in the patients with SA and PFO, there was no significant difference in the time to recurrent stroke or death between the two treatment arms. This was also the case when TIA was included as an additional end point (Table 6 ). When a more stringent criterion of three or more microbubbles was used to define PFO, no significant changes were noted in any of the outcome findings.
DISCUSSION
There are very few studies that have assessed whether the presence of SA and PFO or SA and PFO along with prominent EV or RA filamentous strands increases adverse event rates compared to patients without these findings.
There are a variety of percutaneous devices that may be used for closing PFO in patients with SA, a perceived high-risk group (18, 19) . Before the efficacy of these modalities can be defined, the risk of recurrent stroke or death in medically treated patients needs to be defined. We found that PFO was frequently found in the presence of SA, as was previously noted (30, 31) . We also found that large PFOs are frequently found in the presence of SA with an increased potential for paradoxical embolization. In the past studies, large PFO has been associated with cryptogenic stroke (7, 8) . Thus, the higher stroke risk in patients with SA and PFO may in part derive from the frequent presence of large PFO in patients with SA and PFO. Furthermore, we found that SA is associated with the presence of prominent EV or RA filamentous strands, both remnants of right valve of sinus venosus (12, 13) . In adult life, EV has been associated with cyanosis in patients with atrial septal defect presumably by diverting IVC flow into Homma et al. September 17, 2003 September 17, :1066 Atrial Anatomy and Stroke the left atrium (10, 11) . Chiari network, an extensive network of RA filamentous strands, has been associated with paradoxical embolization, likely by directing embolic material from IVC into the fossa ovalis (15) . We believe these anatomical features in part account for the combination of SA and PFO being strongly associated with stroke. This study is the first to define the relationship between SA with large PFO and EV or RA filamentous strands. This study is also the first to assess the efficacy of medical therapy in double-blind-treated patients with SA and PFO, as well as in patients with SA, PFO, and RA anatomy favoring paradoxical embolization. The PICSS offered a unique opportunity to assess the adverse event rates in a carefully screened cohort of stroke patients (17) . Patients were double-blindly assigned to warfarin or aspirin, and follow-up was conducted using uniform criteria with a very small number of patients lost to follow-up. All TEE studies were centrally and blindly analyzed using uniform criteria.
We have previously reported that on medical therapy the presence of SA in stroke patients with PFO does not increase the adverse event rate beyond that seen with PFO alone (17) . In this study, we further demonstrate that patients with SA and PFO have similar event rates even when compared with those with neither SA nor PFO. Moreover, the presence of EV or RA filamentous strands in patients with PFO and SA did not increase the adverse event rates compared with the patients without any of these findings. Thus while on medical therapy, patients with PFO and SA, as a whole, do not experience increased event rate compared with those without such findings. This implies that either the medical therapy is effective or that the presence of PFO and SA confers a degree of risk not detected by our study.
When warfarin was compared with aspirin in patients with PFO and SA, there was no difference in the adverse event rates between the treatment arms. The mean INR of the warfarin-treated patients in PICSS was 2.04 (17) . In WARSS, an INR Ͼ1.5 proved to be effective in reducing adverse events (22) . Thus, we believe adequate INR was achieved in our population. Prior to events, in patients Abbreviations as in Tables 1 and 3 . Tables 1 and 3 .
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